Neonatal Sepsis: Epidemiology and Management

Pediatric Drugs

Volumn 5, Issue 11, 2003, Pages 723-740

  Baltimore, Robert S ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPICILLIN; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; AZTREONAM; BACTERIAL ANTIGEN; BETA LACTAMASE INHIBITOR; C REACTIVE PROTEIN; CARBAPENEM DERIVATIVE; CD11B ANTIGEN; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CHLORAMPHENICOL; CILASTATIN; CLAVULANIC ACID; GENTAMICIN; IMIPENEM; INTERLEUKIN 6; INTERLEUKIN 8; MEROPENEM; METRONIDAZOLE; OXACILLIN; PENICILLIN DERIVATIVE; SULBACTAM; TAZOBACTAM; TOBRAMYCIN; UNINDEXED DRUG; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL THERAPY; BACTERIAL MENINGITIS; BIRTH WEIGHT; BLOOD CULTURE; CANDIDA; COAGULASE NEGATIVE STAPHYLOCOCCUS; CONGENITAL MALFORMATION; CYTOMEGALOVIRUS; DEVELOPED COUNTRY; DIAGNOSTIC IMAGING; DRUG ACTIVITY; DRUG MECHANISM; DRUG SAFETY; ENTEROCOCCUS; ERYTHROCYTE SEDIMENTATION RATE; ESCHERICHIA COLI; FUNGUS; GESTATIONAL AGE; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE INFECTION; HOSPITAL INFECTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; KLEBSIELLA PNEUMONIAE; LABORATORY TEST; LEUKOCYTE COUNT; LISTERIA MONOCYTOGENES; MYCOSIS; NEWBORN INTENSIVE CARE; NEWBORN SEPSIS; NONHUMAN; PATHOGENESIS; PHYSICAL EXAMINATION; PLACENTAL TRANSFER; PREMATURE FETUS MEMBRANE RUPTURE; PREMATURITY; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; REVIEW; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS; SYPHILIS; TOXOPLASMA GONDII; TREATMENT OUTCOME; VAGINA FLORA; VIRUS DETECTION;

ANTI-BACTERIAL AGENTS; HUMANS; INFANT, NEWBORN; RISK FACTORS; SEPSIS;

EID: 0344011579     PISSN: 11745878     EISSN: None     Source Type: Journal    
DOI: 10.2165/00148581-200305110-00002     Document Type: Review

References (49)

1. Gladstone IM, Ehrenkranz RA, Edberg SC, et al. A ten-year review of neonatal sepsis and comparison with the previous fifty-year experience. Pediatr Infect Dis J 1990; 9: 819-25
2. Almuneef MA, Baltimore RS, Farrel PA, et al. Molecular typing demonstrating transmission of gram-negative rods in a neonatal intensive care unit in the absence of a recognized epidemic. Clin Infect Dis 2001; 32: 221-7
3. Baltimore RS, Huie SM, Meek JI, et al. Early-onset neonatal sepsis in the era of group B streptococcal prevention. Pediatrics 2001; 108: 1094-8
4. Baltimore RS. Perinatal bacterial and fungal infections. In: Jenson HB, Baltimore RS, editors. Pediatric infectious diseases: principles and practice. 2nd ed. Philadelphia (PA): WB Saunders Co., 2002: 1119-34
5. Baltimore RS. Late, late-onset infections in the nursery. Yale J Biol Med 1988; 61: 501-6
6. Klein JO. Bacterial sepsis and meningitis. In: Remington JS, Klein JO, editors. Infectious diseases of the fetus and newborn infant. 5th ed. Philadelphia (PA): WB Saunders Co., 2000: 943-98
7. Centers for Disease Control and Prevention. Prevention of perinatal group B streptococcal disease: revised guidelines from the CDC. MMWR Morb Mortal Wkly Rep 2002; 51 (RR11): 1-12
8. Stoll BJ, Gordon T, Korones SB, et al. Early-onset sepsis in very low birth weight neonates: a report from the National Institute of Child Health and Human Development Neonatal Research Network. J Pediatr 1996; 129: 72-80
9. Cordero L, Sananes M, Ayers LW. Bloodstream infections in a neonatal intensive-care unit: 12 years' experience with an antibacterial control program. Infect Control Hosp Epidemiol 1999; 20: 242-6
10. Schrag SJ, Zywicki S, Farley MM, et al. Group B streptococcal disease in the era of intrapartum antibiotic prophylaxis. New Engl J Med 2000; 342: 15-20
11. Philip AGS. The changing face of neonatal infection: experience at a regional medical center. Pediatr Infect Dis J 1994; 13: 1098-102
12. Beck-Sague CM, Azimi P, Fonseca SN, et al. Bloodstream infections in neonatal intensive care unit patients: results of a multicenter study. Pediatr Infect Dis J 1994; 13: 1110-6
13. Stoll BJ, Gordon T, Korones SB, et al. Late-onset sepsis in very low birth weight neonates: a report for the National Institute of Child Health and Human Development Neonatal Research Network. J Pediatr 1996; 129: 63-71
14. Gaynes RP, Edwards JR, Jarvis WR, et al. Nosocomial infections among neonates in high-risk nurseries in the United States. National Nosocomial Infections Surveillance System. Pediatrics 1996; 98: 357-61
15. Baker CJ, Kasper DL. Correlation of maternal antibody deficiency with susceptibility to neonatal group B streptococcal infection. N Engl J Med 1976; 294: 753-6
16. Edwards MS, Baker CJ. Group B streptococcal infections. In: Remington JS, Klein JO, editors. Infectious diseases of the fetus and newborn infant. 5th ed. Philadelphia (PA): WB Saunders Co., 2000: 1091-156
17. Manroe BL, Weinberg AG, Rosenfeld CR, et al. The neonatal blood count in health and disease (1): reference values for neutrophilic cells. J Pediatr 1979; 95: 89-98
18. Enguix A, Rey C, Concha A, et al. Comparison of procalcitonin with C-reactive protein and serum amyloid for the early diagnosis of bacterial sepsis in critically ill neonates and children. Intensive Care Med 2001; 27: 211-5
19. Hatherill M, Tibby SM, Sykes K, et al. Diagnostic markers of infection: comparison of procalcitonin with C reactive protein and leucocyte count. Arch Dis Child 1999; 81: 417-21
20. Gendrel D, Assicot M, Raymond J, et al. Procalcitonin as a marker for the early diagnosis of neonatal infection. J Pediatr 1996; 128: 570-3
21. Gendrel D, Raymond J, Coste J, et al. Comparison of procalcitonin with C-reactive protein, interleukin 6 and interferon-alpha for differentiation of bacterial vs viral infections. Pediatr Infect Dis J 1999; 18: 875-81
22. Gendrel D, Bohuon C. Procalcitonin as a marker of bacterial infection. Pediatr Infect Dis J 2000; 19 (8): 679-87
23. Mehr S, Doyle LW. Cytokines as markers of bacterial sepsis in newborn infants: a review. Pediatr Infect Dis J 2000; 19: 879-87
24. Ng PC, Cheng SH, Chui KM, et al. Diagnosis of late onset neonatal sepsis with cytokines, adhesion molecule, and C-reactive protein in preterm very low birthweight infants. Arch Dis Child 1997; 77: F221-7
25. Doellner H, Arntzen KJ, Haereid PE, et al. Interleukin-6 concentrations in neonates evaluated for sepsis. J Pediatr 1998; 132: 295-9
26. Franz AR, Steinbach G, Kron M, et al. Reduction of unnecessary antibiotic therapy in newborn infants using interleukin-8 and C-reactive protein as markers of bacterial infections. Pediatrics 1999; 104: 447-53
27. Weirich E, Rabin RL, Maldonado Y, et al. Neutrophil CD11b expression as a diagnostic marker for early-onset neonatal infection. J Pediatr 1998; 132: 445-51
28. Ehl S, Gering B, Bartmann P, et al. C-reactive protein is a useful marker for guiding duration of antibiotic therapy in suspected neonatal bacterial infection. Pediatrics 1997; 99: 216-21
29. Philip AGS, Hewitt JR. Early diagnosis of neonatal sepsis. Pediatrics 1980; 65: 1036-41
30. Philip AGS. Decreased use of antibiotics using a neonatal screening technique. J Pediatr 1981; 98: 795-9
31. Schwersenski J, McIntyre L, Bauer CR. Lumbar puncture frequency and cerebrospinal fluid analysis in the neonate. Am J Dis Child 1991; 145: 54-8
32. Fonseca SNS, Ehrenkranz RA, Baltimore RS. Epidemiology of antibiotic use in a neonatal intensive care unit. Infect Control Hosp Epidemiol 1994; 15: 156-62
33. Young TE, Mangum B. Neofax®: a manual of drugs used in neonatal care. 15th ed. Raleigh (NC): Acorn Publishing, 2002
34. Nelson JD, Bradley JS. 2000-2001 Nelson's pocket book of pediatric antimicrobial therapy. 14th ed. Philadelphia (PA): Lippincott Williams and Wilkins, 2000
35. The medical letter on drugs and therapeutics: handbook of antimicrobial therapy. 16th ed. New York: The Medical Letter, 2002
36. Bryan CS, John Jr JF, Pai S, et al. Gentamicin vs cefotaxime for therapy of neonatal sepsis: relationship to drug resistance. Am J Dis Child 1985; 139: 1086-9
37. De Man P, Verhoeven BAN, Verbrugh HA, et al. An antibiotic policy to prevent emergence of resistant bacilli. Lancet 2000; 355: 973-8
38. Reed MD, Blumer JL. Anti-infective therapy. In: Jenson HB, Baltimore RS, editors. Pediatric infectious diseases: principles and practice. 2nd ed. Philadelphia (PA): WB Saunders Co, 2002: 147-215
39. Vitale R, Baltimore RS. Pediatric aminoglycoside dosing guidelines. New Haven (CT): Yale-New Haven Hospital, 2002
40. Cairo MS, Worcester CC, Rucker RW, et al. Randomized trial of granulocyte transfusion versus immune globulin therapy for neonatal neutropenia and sepsis. J Pediatr 1992; 120: 281-5
41. Miura E, Procianoy RS, Bittar C, et al. A randomized, double-masked, placebo-controlled trial of recombinant granulocyte colony-stimulating factor administration to preterm infants with the clinical diagnosis of early-onset sepsis. Pediatrics 2001; 107: 30-5
42. Bilgin K, Yaramis A, Haspolat K, et al. A randomized trial of granulocyte-macrophage colony-stimulating factor in neonates with sepsis and neutropenia. Pediatrics 2001; 107: 36-41
43. Bernstein HM, Calhoun DA, Christensen RD. Use of myeloid colony-stimulating factors in neonates with septicemia. Curr Opin Pediatr 2002; 14: 91-4
44. Berger M. Use of intravenously administered immune globulin in newborn infants: prophylaxis, treatment, both, or neither? J Pediatr 1991; 118: 557-9
45. Jenson HB, Pollock BH. Meta-analyses of the effectiveness of intravenous immune globulin for the prevention and treatment of neonatal sepsis. Pediatrics 1997; 99 (2): E2
46. Giroir BP. Recombinant human activated protein C for the treatment of severe sepsis: is there a role in pediatrics? Curr Opin Pediatr 2003; 15: 92-6
47. Van den Anker JN, van Popele NML, Sauer PJJ. Antifungal agents in neonatal systemic candidiasis. Antimicrob Agents Chemother 1995; 39: 1391-7
48. Sanchez PJ, Siegel JD, Fishein J. Candida endocarditis: successful medical management in three preterm infants and review of the literature. Pediatr Infect Dis J 1991; 10: 239-43
49. Butler KM, Rench MA, Baker CJ. Amphotericin B as a single agent in the treatment of systemic candidiasis in neonates. Pediatr Infect Dis J 1990; 9: 51-6